$3.17T
Total marketcap
$151.18B
Total volume
BTC 56.90%     ETH 12.18%
Dominance

Eli Lilly and Company LLY Stock

$993.64   1.162680%
Add to favorites
Exchange
Market Cap
$890.76B
LOW - HIGH [24H]
$977.12 - $1,003.00
VOLUME [24H]
$2.94M
P/E Ratio
48.77
Earnings per share
$20.37
Price   Prediction

Eli Lilly and Company Price Chart

Sorry, that's all we've gotfor now...

Eli Lilly and Company LLY Financial and Trading Overview

Eli Lilly and Company stock price 993.64 USD
Previous Close 573.67 USD
Open 572.1 USD
Bid 571.21 USD x 800
Ask 572.1 USD x 1200
Day's Range 561.65 - 573.71 USD
52 Week Range 309.2 - 629.97 USD
Volume 5.32M USD
Avg. Volume 3.27M USD
Market Cap 543.04B USD
Beta (5Y Monthly) 0.331
PE Ratio (TTM) 104.196724
EPS (TTM) 20.37 USD
Forward Dividend & Yield 5.2 (0.91%)
Ex-Dividend Date February 14, 2024
1y Target Est 635.67 USD

LLY Valuation Measures

Enterprise Value 532.23B USD
Trailing P/E 104.196724
Forward P/E 46.13226
PEG Ratio (5 yr expected) 3.01
Price/Sales (ttm) 16.931688
Price/Book (mrq) 45.847557
Enterprise Value/Revenue 16.595
Enterprise Value/EBITDA 47.033

Trading Information

Eli Lilly and Company Stock Price History

Beta (5Y Monthly) 0.331
52-Week Change N/A
S&P500 52-Week Change N/A
52 Week High 629.97 USD
52 Week Low 309.2 USD
50-Day Moving Average 588.97 USD
200-Day Moving Average 484.69 USD

LLY Share Statistics

Avg. Volume (3 month) 3.27M USD
Avg. Daily Volume (10-Days) 3.35M USD
Shares Outstanding 949.31M
Float 897.74M
Short Ratio 1.56
% Held by Insiders 0.15%
% Held by Institutions 84.37%
Shares Short 5.52M
Short % of Float 0.69%
Short % of Shares Outstanding 0.57%

Dividends & Splits

Trailing Annual Dividend Rate 4.37
Trailing Annual Dividend Yield 0.76%
5 Year Average Dividend Yield 153.00%
Payout Ratio 0.7917
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) September 30, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 15.55%
Operating Margin (ttm) 37.27%
Gross Margin 78.66%
EBITDA Margin 35.28%

Management Effectiveness

Return on Assets (ttm) 11.62%
Return on Equity (ttm) 46.46%

Income Statement

Revenue (ttm) 32.07B USD
Revenue Per Share (ttm) 35.62 USD
Quarterly Revenue Growth (yoy) 36.79%
Gross Profit (ttm) 21.91B USD
EBITDA 11.32B USD
Net Income Avi to Common (ttm) 4.99B USD
Diluted EPS (ttm) 5.49
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.62B USD
Total Cash Per Share (mrq) 2.92 USD
Total Debt (mrq) 20.33B USD
Total Debt/Equity (mrq) 179.81 USD
Current Ratio (mrq) 1.046
Book Value Per Share (mrq) 12.477

Cash Flow Statement

Operating Cash Flow (ttm) 5.71B USD
Levered Free Cash Flow (ttm) 3.9B USD

Profile of Eli Lilly and Company

Country United States
State IN
City Indianapolis
Address Lilly Corporate Center
ZIP 46285
Phone 317 276 2000
Website https://www.lilly.com
Industry Drug Manufacturers-General
Sector(s) Healthcare
Full Time Employees 39000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Q&A For Eli Lilly and Company Stock

What is a current LLY stock price?

Eli Lilly and Company LLY stock price today per share is 993.64 USD.

How to purchase Eli Lilly and Company stock?

You can buy LLY shares on the NYSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Eli Lilly and Company?

The stock symbol or ticker of Eli Lilly and Company is LLY.

Which industry does the Eli Lilly and Company company belong to?

The Eli Lilly and Company industry is Drug Manufacturers-General.

How many shares does Eli Lilly and Company have in circulation?

The max supply of Eli Lilly and Company shares is 896.46M.

What is Eli Lilly and Company Price to Earnings Ratio (PE Ratio)?

Eli Lilly and Company PE Ratio is 48.77957500 now.

What was Eli Lilly and Company earnings per share over the trailing 12 months (TTM)?

Eli Lilly and Company EPS is 20.37 USD over the trailing 12 months.

Which sector does the Eli Lilly and Company company belong to?

The Eli Lilly and Company sector is Healthcare.

Eli Lilly and Company LLY included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
S&P 500 INDEX SPX 6886.68 USD
+0.67
3.55B USD 3.55B USD
S&P 500 (Yahoo.com) GSPC 6886.68 USD
+0.67
3.51B USD 6824.69 USD 6900.67 USD 3.51B USD
S&P 100 SP100 3450.93 USD
+0.43
1.63B USD 3422.69 USD 3457.29 USD 1.63B USD
US Tech CRD Global Sustainabilit NQCRD 1735.62 USD
0
1715.94 USD 1757.95 USD
The Capital Strength Index NQCAPST 3374.86 USD
+0.98
3346.51 USD 3378.82 USD
NYSE Arca Pharmaceutical Index DRG 1083.19 USD
+1.7
US Tech OMX CRD Global Sustainab QCRD 1595.1 USD
0
US Tech US Smart Pharmaceuticals NQSSPH 1715.45 USD
+1.53
1687.01 USD 1718.94 USD
US Tech Factor Family US Low Vol NQFFUSLV 1688.57 USD
+0.31
1680.35 USD 1692.42 USD
US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
The Capital Strength Net Total NQCAPSTN 4005.44 USD
+0.98
3971.74 USD 4010.17 USD
NYSE Composite Index NYA 21933.31 USD
+1.29
US Tech US Price Setters Index NQPRCE 2899.07 USD
+0.8
2878.12 USD 2906.67 USD
US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG 3535.18 USD
+1.06
3488.91 USD 3554.31 USD
✨New! Portfolio🚀